Alvotech

ALVO Healthcare Drug Manufacturers Specialty & Generic

Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,311.0%, EPS fell 99.5%, free cash flow fell 496.6% and total debt rose 16.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

5.00 0.31 −5.84%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
8.9×
Dividend yield
—
F-score
3/9
Altman Z
−0.98
Beneish M
−2.68
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— 5 — —

+8 more TTM periods

ROE
0.00% 101.38% 0.00% 0.00%
ROA
0.00% (22.23%) 0.00% 0.00%
ROIC
0.00% (8.07%) 0.00% 0.00%
Return on Tangible Assets
0.00% (53.26%) 0.00% 0.00%
Average Days of Receivables
0.00 60.34 0.00 0.00
Free Cash Flow per Share
0.00 (0.54) — 0.00
Free Cash Flow
(211.69) (157.95) — (274.92)
Other line items

Show all line items

Columns are period end dates